Role of probiotics in the treatment of inflammatory bowel disease (IBD)

Agro Food Industry Hi-Tech

Volumn 18, Issue 3, 2007, Pages 13-16

  Hojsak, Iva ^a   Kekez, Alemka Jaklin ^a   Kolacek, Sanja ^a  

^a Children's University Hospital Zagreb   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED TRIAL; CROHN'S DISEASE; IMMUNOLOGICAL EFFECTS; INFLAMMATORY BOWEL DISEASE; PROBIOTICS; ULCERATIVE COLITIS;

FOOD TECHNOLOGY;

DISEASES;

EID: 34547158662     PISSN: 17226996     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. O.C. Thompson-Chagoyan, J. Maldonado, A. Gil. Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr 24(3), 339-52, (2005).
2. M.C. Dubinsky, K. Taylor, S.R. Targan, J.I. Rotter. Immunogenetic phenotypes in inflammatory bowel disease. World J Gastroenterol 12(23), 3645-50, (2006).
3. R.S. Blumberg, W. Strober. Prospects for research in inflammatory bowel disease. JAMA 285(5), 643-7 (2001).
4. J. E. Teitelbaum, W.A. Walker. Nutritional impact of pre- and probiotics as protective gastrointestinal organisms. Annu Rev Nutr 22, 107-38 (2002).
5. R.I. Mackie, A. Sghir, H.R.Gaskins. Developmental microbial ecology of the neonatal gastrointestinal tract. Am J Clin Nutr 69(5), 1035-1045, (1999).
6. F. Guarner, J.R. Malagelada. Gut flora in health and disease. Lancet 361(9356), 512-9 (2003).
7. Y. Umesaki, H. Setoyama. Structure of the intestinal flora responsible for development of the gut Immune system in a rodent model. Microbes Infect 2(11), 1343-51, (2000).
8. K.S. Michelsen, M. Arditi. Toll-like receptors and innate immunity in gut homeostasis and pathology. Curr Opin Hematol 14(1), 48-54 (2007).
9. A. Sato, A. Iwasaki. Peyera patch dendritic cells as regulators of mucosal adaptive immunity. Cell Mol Life Sci 62(12), 1333-8, (2005).
10. K. Kukkonen, E. Savilahti, T. Haahtela, K. Juntunen-Backman, R. Korpela, T. Poussa, T. Tuure, M. Kuitunen. Probiotics and prebiotic galacto- oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 119(1), 192-8, (2007).
11. R.L. Jump, A.D. Levine. Mechanisms of natural tolerance in the intestine: implications for inflammatory bowel disease. Inflamm Bowel Dis 10(4), 462-78, (2004).
12. R.J. Farrell, J.T. LaMont. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am 31(1), 41-62 (2002).
13. S.B. Sartor. Pathogenesis and immune mechanisms of chronic inflammatory bowel diseases. Am J Gastroenterol 92(12), 5-11, (1997).
14. F. Casellas, N. Borruel, M. Papo, F. Guarner, M. Antolin, S. Videla, J.R. Malagelada. Antiinflammatory effects of enterically coated amoxicillin- clavulanic acid in active ulcerative colitis. Inflamm Bowel Dis 4(1), 1-5, (1998).
15. J.B. Ewaschuk, Q.Z. Tejpar, I. Soo, K. Madsen, R.N. Fedorak. The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. Curr Gastroenterol Rep 8(6), 486-98, (2006).
16. P. Seksik, H. Sokol, P. Lepage, N. Vasquez, C. Manichanh, I. Mangin, P. Pochart, J. Dore, P. Marteau. Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther 24(3), 11-8, (2006).
17. P. Seksik, L. Rigottier-Gois, G. Gramet et al. Alterations of the ominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 52, 237-42, (2003).
18. J.H. Cummings, G.T. Macfarlane, S. Macfarlane. Intestinal bacteria and ulcerative colitis. Curr Issues Intest Microbiol 4, 9-20, (2003).
19. C. Neut, P. Bulois, P. Desreumaux, J.M. Membre, E. Lederman, L. Gambiez, A. Cortot, P. Quandalle, H. van Kruiningen, J.F. Colombel. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol 97, 939-946, (2002).
20. M.H. Giaffer, C.D. Holdsworth, B.I. Duerden. The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique. J Med Microbiol 35, 238-43, (1991).
21. A.P. Bai, Q. Ouyang. Probiotics and inflammatory bowel diseases. Postgrad Med J 82(968), 376-82, (2006).
22. P. Rutgeerts, K. Goboes, M. Peeters, M. Hiele, F Penninckx, R. Aerts, R. Kerremans, G. Vantrappen. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 338(8770), 771-4, (1991).
23. G.R. D'Haens, K. Geboes, M. Peeters, F. Baert, F. Penninckx, P. Rutgeerts. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 114(2), 262-7, (1998).
24. A. Macpherson, U.Y. Khoo, I. Forgacs, J. Philpott-Howard, I. Bjarnason. Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria. Gut 38, 365-375, (1996).
25. R. Duchmann, E. May, M. Heike, P. Knolle, M. Neurath, K.H. Meyer zum Buschenfelde. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut 44(6), 812-8, (1999).
26. A.L. Hart, A.J. Stagg, M. Frame, H. Graffner, H. Glise, P. Falk, M.A. Kamm. The role of the gut flora in health and disease, and its modification as therapy. Aliment Pharmacol Ther 16(8), 1383-93, (2002).
27. N. Inohara, Y. Ogura, A. Fontalba et al. Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease. J Biol Chem 278, 5509-5512, (2003).
28. M. Schmid, K. Fellermann, J. Wehkamp J, et al. The role of defensins in the pathogenesis of chronic-inflammatory bowel disease. Z Gastroenterol 42, 333-338, (2004).
29. J. Wehkamp, J. Harder, M. Weichenthal, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 53, 1658-1664, (2004).
30. O. Kanauchi, Y. Matsumoto, M. Matsumura, M. Fukuoka, T. Bamba. The beneficial effects of microflora, especially obligate anaerobes, and their products on the colonic environment in inflammatory bowel disease. Curr Pharm Des 11(8), 1047-53, (2005).
31. G.T Macfarlane, J.H. Cummings. Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? Br Med J 318, 999-1003, (1999).
32. M.D. Collins, G.R. Gibson. Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 69, 1052-1057, (1999).
33. M.A. Gassull. Review article: the intestinal lumen as a therapeutic target In inflammatory bowel disease. Aliment Pharmacol Ther 24 (3), 90-5, (2006).
34. S. Drouault-Holowacz, B. Foligne, V. Dennin, D. Goudercourt, K. Terpend, A. Burckel, B. Pot. Anti-inflammatory potential of the probiotic dietary supplement Lactibiane Tolerance: in vitro and in vivo considerations. Clin Nutr 25(6), 994-1003, (2006).
35. J.A. Katz. Advances in the medical therapy of inflammatory bowel disease. Curr Opin Gastroenterol 18(4), 435-40, (2002).
36. W. Kruis, E. Schutz, P. Fric, B. Fixa, G. Judmaier, M. Stolte. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997 11(5), 853-8, (2002).
37. B.J. Rembacken, A.M. Snelling, P.M. Hawkey, D.M. Chalmers, A.T. Axon. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354(9179), 635-9, (1999).
38. W. Kruis, P. Fric, J. Pokrotnieks, M. Lukas, B. Fixa, M. Kascak, M.A. Kamm, J. Weismueller, C. Beglinger, M. Stolte, C. Wolff, J. Schulze. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53(11), 1617-23, (2004).
39. H. Ishikawa, I. Akedo, Y. Umesaki, R. Tanaka, A. Imaoka, T. Otani. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 22(1), 56-63, (2003).
40. H.H. Cui, C.L. Chen, J.D. Wang, Y.J. Yang, Y. Cun, J.B. Wu, Y.H. Liu, H.L. Dan, Y.T. Jian, X.Q. Chen. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis. World J Gastroenterol 10(10), 1521-5, (2004).
41. R. Bibiloni, R.N. Fedorak, G.W. Tannock, K.L. Madsen, P. Gionchetti, M. Campieri, C. De Simone, R.B. Sartor. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 100(7), 1539-46, (2005).
42. A. Tursi, G. Brandimarte, G.M. Giorgetti, G. Forti, M.E. Modeo, A. Gigliobianco. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10(11), 126-31, (2004).
43. P. Gionchetti, F. Rizzello, A. Venturi, P. Brigidi, D. Matteuzzi, G. Bazzocchi, G. Poggioli, M. Miglioli, M. Campieri. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119(2), 305-9, (2000).
44. T. Mimura, F. Rizzello, U. Helwig, G. Poggioli, S. Schreiber, I.C. Talbot, R.J. Nicholls, P. Gionchetti, M. Campieri, M.A. Kamm. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53(1), 108-14, (2004).
45. P. Gionchetti, F. Rizzello, U. Helwig, A. Venturi, K.M. Lammers, P. Brigidi, B. Vitali, G. Poggioli, M. Miglioli, M. Campieri. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebocontrolled trial. Gastroenterology 124(5), 1202-9, (2003).
46. T. Kuhbacher, S.J. Ott, U. Helwig, T. Mimura, F. Rizzello, B. Kleessen, P. Gionchetti, M. Blaut, M. Campieri, U.R. Folsch, A.M. Kamm, S. Schreiber. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 55(6), 833-41, (2006).
47. J. Kuisma, S. Mentula, H. Jarvinen, A. Kahri, M. Saxelin, M. Farkkila. Effect of Lactobacillus rhamnosus GG on ileal pouch Inflammation and microbial flora. Aliment Pharmacol Ther 17(4), 509-15, (2003).
48. A. Bousvaros, S. Guandalini, R.N. Baldassano, C. Botelho, J. Evans, G.D. Ferry, B. Goldin, L. Hartigan, S. Kugathasan, J. Levy, K.F. Murray, M. Oliva-Hemker, J.R. Rosh, V. Tolia, A. Zholudev, J.A. Vanderhoof, P.L. Hibberd. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 11(9), 833-9, (2005).
49. M. Schultz, A. Timmer, H.H. Herfarth, R.B. Sartor, J.A. Vanderhoof, H.C. Rath.Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 15, 4-5, (2004).
50. P. Marteau, M. Lemann, P. Seksik, D. Laharie, J.F Colombel, Y. Bouhnik, G. Cadiot, J.C. Soule, A. Bourreille, E. Metman, E. Lerebours, F. Carbonnel, J.L. Dupas, M. Veyrac, B. Coffin, J. Moreau, V. Abitbol, S. Blum-Sperisen, J.Y. Mary. Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut 55(6), 842-7, (2006).
51. C. Prantera, M.L. Scribano, G. Falasco, A. Andreoli, C. Luzi. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a random ised controlled trial with Lactobacillus GG. Gut 51(3), 405-9, (2002).
52. M. Campieri, F. Rizzello, A. Venturi, G. Poggioli, F. Ugolini, U. Helwig, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study versus mezalamine. Gastroenterology 118(4), A781, (2000).
53. V.E. Rolfe, P.J. Fortun, C.J. Hawkey, F. Bath-Hextall. Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 18(4), CD004826 (2006).